Thanks to our partner, Mochi Health! https://JoinMochi.com
In this episode of Hims House, Jonathan Stern sits down with Sabina Hemmi (founder of GLP Winner), for the most comprehensive episode on GLP-1s that Hims House has done. They cover the compounding wars -- federal legislation, state-level crackdowns, and the lawsuits -- before diving into why tirzepatide dominates patient demand and what might be holding Hims back from offering it. The discussion spans oral GLP-1s, microdosing trends, and concludes with Sabina's skeptical take on peptides.
00:00 - Sponsor: Mochi Health
02:59 - Video games → GLP-1s
04:56 - GLP Winner Overview
10:28 - Who does Hims actually compete with?
16:43 - Hims x Novo Relationship
23:17 - Why tirzepatide is superior
29:30 - The SAFE Drugs Act
32:23 - State Bills: Indiana, Florida, Virginia
40:43 - Adverse events
43:09 - GLP-1 pill vs. injectables
50:57 - Over-the-Counter GLP-1 coming soon?
52:55 - Peptides
Not financial, legal, or medical advice
Subscribe to Hims House:
https://himshouse.com/subscribe
Follow Sabina:
Tiktok: https://www.tiktok.com/@lawliepop
Instagram: https://www.instagram.com/lawliepops
Youtube: https://www.youtube.com/@lawliepop
X/Twitter: https://x.com/lawliepop
Substack: https://substack.com/@lawliepop
Linkedin: https://www.linkedin.com/in/sabina-hemmi
Follow us:
https://x.com/himshouse
https://x.com/jonathanrstern
Join the Discord:
https://discord.gg/tJqGgVhkEt